-
Adicon Holdings and Guardant Health Partner on Genomic Profiling in China
•
China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant’s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant’s liquid biopsy technology, including the Guardant360,…
-
BeiGene and InnoRNA Partner on mRNA-LNP Therapeutic Development
•
China-based biotech firm BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) announced a strategic partnership with compatriot company InnoRNA, a specialist in lipid-nanoparticle (LNP)-based delivery technology and mRNA drug discovery. The collaboration aims to leverage InnoRNA’s innovative platform for developing mRNA-based therapeutics. Agreement TermsUnder the deal, InnoRNA will receive an upfront…
-
PackGene and SineuGene Partner on ALS Gene Therapy Research
•
China-based PackGene has entered into another partnership with compatriot firm SineuGene. This time, the focus is on plasmid pharmaceutical research, adeno-associated virus (AAV) pharmaceutical research, AAV batch release testing, analytical methodology development, stability research, and more. The collaboration aims to support SineuGene’s lead pipeline candidate SG001, a genetic therapy under…
-
China Establishes Leadership Group to Combat Drug-Related Crimes
•
China’s State Council executive body released a notification regarding the establishment of a leadership group aimed at cracking down on crimes that could impact drug safety and endanger the public. The group will consist of several State Council deputies and leaders from key government agencies, including the National Medical Products…
-
Phil Rivers Tech Raises RMB 100 Million for Computational Medicine Push
•
Beijing-based Phil Rivers Tech, a computational medicine-empowered drug developer, reportedly raised close to RMB 100 million (USD 14.9 million) in a Series A financing round. The funding was led by Insight Capital and Tenaya Capital, with participation from Highthink Med. The proceeds will be used for the upgrade of its…
-
Gan & Lee Pharmaceuticals Doses First Patient in GZR101 Phase I Study
•
China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that the first patient has been dosed in a China-based Phase I clinical study for its drug candidate GZR101. The first-in-human study aims to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of the GZR101 injection and its component GZR33. Drug Details and…
-
Fosun Pharma’s FS-1502 Gets NMPA Approval for Gastric Cancer Study
•
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a Phase II clinical study for its HER2 monoclonal antibody (mAb) injection FS-1502 in HER2-expressing advanced gastric cancer patients. The study will evaluate the…
-
GeneScience’s Somatropin Wins NMPA Approval for Prader-Willi Syndrome
•
China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another indication approval from the National Medical Products Administration (NMPA) for its somatropin to treat Prader-Willi Syndrome (PWS). This latest approval marks the tenth indication for the company’s somatropin and represents the first approval for a home-grown growth hormone…
